×

Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor

  • US 9,914,923 B2
  • Filed: 01/01/2015
  • Issued: 03/13/2018
  • Est. Priority Date: 05/18/2009
  • Status: Active Grant
First Claim
Patent Images

1. A pharmaceutical composition comprising a synthetic, modified oligonucleotide of 10 to 30 nucleotides in length comprising at least one modification wherein the at least one modification is selected from:

  • at least one modified sugar moiety;

    at least one modified internucleotide linkage;

    at least one modified nucleotide, and combinations thereof;

    wherein said oligonucleotide is an antisense compound which is 100% complementary to and specifically hybridizes to a complementary region of a natural antisense polynucleotide of a Reprogramming Factor gene selected from SEQ ID NOS;

    4 or 5 and upregulates the function and/or expression of the Reprogramming factor gene in vivo or in vitro as compared to a normal control and a pharmaceutically acceptable excipient.

View all claims
  • 1 Assignment
Timeline View
Assignment View
    ×
    ×